Form 4 for AKTX Akari Therapeutics Plc
Accepted 2026-07-17 06:03:07 ET · period of report 2026-07-07 · accession 0001493152-26-033634 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-07-17 06:03 | 2026-07-07 | AKTX | Patel Samir Rashmikant | Dir, 10% | M - OptEx | $0.4307 | +22.5K | 98.2K | +30% | +$9,681 |
| DMI | 2026-07-17 06:03 | 2026-07-07 | AKTX | Patel Samir Rashmikant | Dir, 10% | M - OptEx | $17.01 | +22.5K | 0 | New | +$382.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2026-07-07 | M | A | 1,209 | $8.00 | 76,976 | I PranaBio Investments LLC | — | — | |
| 2 | Common | American Depositary Shares representing Ordinary Shares | 2026-07-07 | M | A | 15,466 | $0.0004 | 92,442 | I PranaBio Investments LLC | — | — | |
| 3 | Common | American Depositary Shares representing Ordinary Shares | 2026-07-07 | M | A | 5,799 | $0.0004 | 98,241 | I PranaBio Investments LLC | — | — | |
| 4 | Derivative | Pre-Funded Warrant to purchase American Depositary Shares | 2026-07-07 | M | A | 1,209 | $32.00 | 0 | I PranaBio Investments LLC | $8.00 · 2023-10-06 to — | 1,209 American Depositary Shares representing Ordinary Shares | (F1) Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. (F2) The pre-funded warrants remain exercisable until fully exercised. |
| 5 | Derivative | Pre-Funded Warrant to purchase ADSs | 2026-07-07 | M | A | 15,466 | $16.16 | 0 | I PranaBio Investments LLC | $0.0004 · — to — | 15,466 American Depositary Shares representing Ordinary Shares | (F4) The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16. (F3) The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. (F2) The pre-funded warrants remain exercisable until fully exercised. |
| 6 | Derivative | Pre-Funded Warrant to purchase ADSs | 2026-07-07 | M | A | 5,799 | $16.16 | 0 | I PranaBio Investments LLC | $0.0004 · — to — | 5,799 American Depositary Shares representing Ordinary Shares | (F5) On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs. (F5) On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs. (F3) The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026. (F2) The pre-funded warrants remain exercisable until fully exercised. |